Antares Receives FDA Approval of Xyosted™ (Testosterone Enanthate) Injection for Testosterone Replacement Therapy in Adult Males
October 01, 2018 07:00 ET
|
Antares Pharma, Inc.
A Novel Subcutaneous Auto Injector Product Approved For Once-Weekly At-Home Therapy EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the approval...
Antares Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg...
Antares Pharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
August 30, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman &...
Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector
August 16, 2018 16:54 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that the U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical...
Antares Pharma Reports Second Quarter 2018 Operating and Financial Results
August 07, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the second quarter ended June 30, 2018. The...
Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer
August 06, 2018 16:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of...
Antares Pharma Enters Into Development Agreement With Pfizer Inc.
August 06, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) today announced that it has entered into an agreement with Pfizer Inc. (“Pfizer”) to develop a...
Antares Pharma to Report Second Quarter 2018 Financial and Operating Results
July 31, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2018 financial results and recent operating progress before the...
Antares Pharma Announces Receipt of Third Installment From Sale of ZOMAJET™ Needle-Free Delivery System
May 30, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (“Antares”) (“The Company”) today announced that it has received $4.75 million from Ferring Pharmaceuticals...
Antares Pharma to Present at the Jefferies 2018 Healthcare Conference
May 29, 2018 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2018...